7. Caribou Biosciences (NASDAQ:CRBU)
Caribou Biosciences ranks No. 7 because it sits in one of the most exciting and complicated areas of modern medicine: gene editing and cell therapy. With shares around $2.36 and a market capitalization of about $226 million, CRBU has the profile of a small-cap biotech penny stock that still carries meaningful scientific ambition. It is not a commercial-stage comfort pick. It is a clinical-stage biotech stock where the reward depends on whether the company’s technology can continue moving toward stronger data and regulatory progress.
The key part of the story is FDA alignment on the pivotal ANTLER-3 trial design for vispa-cel in second-line LBCL. For a casual reader, that may sound like heavy medical jargon. But in biotech investing, FDA alignment on a pivotal trial design matters because it can reduce uncertainty around what the company needs to show next. It does not guarantee success, but it gives investors a clearer framework. The market likes clarity, especially in areas as complex as cell therapy.
CRBU’s appeal comes from the fact that cell therapy remains one of the most watched fields in oncology. Investors know that cancer treatment has been moving toward more targeted and personalized approaches, and cell therapy has already produced major breakthroughs across certain blood cancers. If Caribou’s programs continue to show meaningful progress, the stock could attract attention from biotech investors looking for gene-editing stocks, oncology penny stocks, and small-cap cell therapy stocks with takeover or partnership potential.
But the risk remains high. Clinical-stage cell therapy companies are expensive to run. Trials take time. Manufacturing can be complex. Safety, durability, and competitive positioning all matter. CRBU does not have the same revenue base as the commercial-stage companies higher on this list, so investors are still betting heavily on future outcomes. In biotech, that can create powerful upside, but it also means a single disappointing update can damage the entire thesis.
This is why Caribou deserves its No. 7 ranking. It is more speculative than the commercial-stage names, but its risk/reward is interesting because the valuation remains small while the medical opportunity could be meaningful if the data continues to cooperate. For investors searching for the best gene-editing penny stocks or top biotech stocks under $5 this June, CRBU is one of the names that deserves a closer look.
Click next to see the following stock...
